FDA Clears Satellos IND for Forazapadin in FSHD, Phase 2 Trial Set for Q4 2026
核心洞察
The FDA has cleared Satellos Bioscience (搜索)'s IND application for forazapadin (搜索) in facioscapulohumeral muscular dystrophy (搜索), the second clinical indication for the AAK1 (搜索) inhibitor.
Satellos plans to begin a randomized, double-blind, placebo-controlled Phase 2 study in adults with FSHD in the fourth quarter of 2026.
The trial will test oral forazapadin (搜索) at 60 mg and 120 mg doses, assessing safety, tolerability, pharmacokinetics and potential efficacy in patients aged 18 and older.
Satellos Bioscience (搜索) has received FDA clearance of its Investigational New Drug application for forazapadin (搜索) in facioscapulohumeral muscular dystrophy (搜索) (FSHD), opening a second clinical indication for the oral small molecule AAK1 (搜索) inhibitor. The Toronto-based clinical-stage company said it plans to initiate a Phase 2 study in FSHD in the fourth quarter of 2026.
The clearance permits Satellos to proceed with clinical testing of forazapadin (搜索) in FSHD. It does not constitute FDA approval of the candidate for the treatment of FSHD.
Trial Design and Dosing
The planned FSHD study is a randomized, double-blind, placebo-controlled proof-of-concept trial of orally administered forazapadin (搜索) in adults aged 18 and older living with FSHD. It will evaluate 60 mg and 120 mg doses and assess safety, tolerability, pharmacokinetics and potential efficacy.
Wildon Farwell, chief medical officer of Satellos, said the agency's clearance included both dose levels. "We are excited to receive FDA clearance of our IND application for forazapadin (搜索) in a second disease indication, one for which there are currently no approved therapies," he said. "In particular, we are delighted that the clearance included 60 mg and 120 mg dose levels of forazapadin, enabling evaluation of two doses of our small molecule drug candidate."
FSHD Disease Burden and Unmet Need
FSHD is one of the most common forms of muscular dystrophy, affecting an estimated 800,000 individuals worldwide. The condition is caused by abnormal activation of the DUX4 (搜索) gene, which damages muscle and contributes to progressive muscle weakness. Symptoms often begin in the muscles of the face, shoulders and upper arms before progressing to other parts of the body. Severity and rate of progression vary between patients, and there are currently no approved disease-modifying therapies.
Satellos describes FSHD as a genetic disease in which muscle regeneration appears to be compromised. "We look forward to working with the FSHD community to evaluate the potential of forazapadin (搜索) to impact muscle regeneration and benefit people living with FSHD," Farwell said.
Non-Dilutive Financing from FSHD Canada Foundation
Alongside the IND clearance, Satellos announced a financing agreement with the FSHD Canada Foundation (搜索), a Calgary-based charitable organization. The Foundation has agreed to contribute up to US$5 million in milestone payments over the next five quarters in exchange for a capped revenue-sharing interest in future FSHD-related proceeds. Satellos described the arrangement as non-dilutive, and the amount ultimately received will depend on achievement of the applicable milestones.
Neil Camarta, co-founder of the FSHD Canada Foundation (搜索), framed the agreement around patient priorities. "People living with FSHD, like me, are eager to find treatments that can stop our muscles from getting weaker. But we would also like to get some of those muscles back," he said. "Seeing forazapadin (搜索) advance into clinical trials to evaluate the potential for muscle regeneration in FSHD is an important step for our community. While we know there is still a long road ahead, it is encouraging to see innovative approaches like this moving into the clinic."
Frank Gleeson, co-founder and chief executive officer of Satellos, said the expansion reflects the breadth of the company's approach. "We believe the biology targeted by forazapadin (搜索) has the potential to address significant unmet needs in degenerative muscle diseases, and our expansion into FSHD reflects the broad potential of our muscle regeneration approach," he said.
AAK1 Inhibition and the DMD Program
Forazapadin (搜索), previously referred to as SAT-3247, targets AAK1 (搜索), a protein Satellos believes has a role in muscle repair and regeneration. By inhibiting AAK1, the company aims to re-establish a biochemical signal believed to support muscle regeneration. Satellos expects to transition to broader use of the program's International Nonproprietary Name in future scientific, regulatory and corporate communications.
The candidate is already being evaluated in two ongoing Phase 2 trials in Duchenne muscular dystrophy (搜索) (DMD): BASECAMP, a global, randomized, placebo-controlled study in pediatric participants, and TRAILHEAD, an open-label study in adults. Satellos is advancing forazapadin (搜索) as a potential DMD treatment that is independent of dystrophin and applicable regardless of exon mutation status, either as a stand-alone or adjunctive therapy.
Preliminary data from the ongoing Phase 2 adult DMD study showed a favorable safety profile, reduced muscle fat fraction as measured by MRI, and increased total effort after six months of treatment at 60 mg. The company believes these findings may be consistent with muscle regeneration. Satellos noted that these preliminary observations come from an ongoing clinical development program and do not establish the safety or efficacy of forazapadin (搜索).
Forazapadin (搜索) remains investigational and has not been approved for the treatment of FSHD or DMD. Satellos said it has identified additional muscle diseases and injury conditions where restoring muscle repair and regeneration may have therapeutic benefit and plans to pursue these opportunities in future clinical development.